Misoprostol

證據等級: L5

預測適應症: 2 個

Misoprostol: From Labour Induction/Pregnancy Termination to Amenorrhea

One-Sentence Summary

Misoprostol is a PGE1 analogue whose established clinical roles — per the evidence pack’s own mechanistic notes — are inducing uterine contractions, cervical ripening, and (combined with mifepristone) pregnancy termination/missed abortion management. The TxGNN model predicts it may be effective for amenorrhea (disease), with 0 clinical trials and 7 publications currently associated with this pairing — and critically, none of those publications study misoprostol as a treatment for amenorrhea. The evidence pack itself flags this as a likely knowledge-graph proximity artifact rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	Not available — the pack contains no `original_indications` or Taiwan/SAHPRA licence text; known clinical role (per rationale notes) is labour induction / cervical ripening / pregnancy termination
Predicted New Indication	Amenorrhea (disease)
TxGNN Prediction Score	99.64%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this pack (flagged as a Blocking/High-severity data gap). Based on the mechanistic notes that are available, misoprostol is a PGE1 analogue whose pharmacological effect is to induce uterine contraction and cervical softening — i.e., to promote expulsion of uterine contents and bleeding. This is the mechanism exploited for labour induction, cervical preparation, and (with mifepristone) termination of pregnancy or management of missed abortion.

Amenorrhea, by contrast, generally requires mechanisms that restore or induce a menstrual cycle (hormonal regulation), which is functionally the opposite of what misoprostol does. The evidence pack’s own repurposing rationale is explicit on this point: the seven associated publications are almost entirely about medical abortion, missed abortion, and endometrial ablation for heavy bleeding — not about treating amenorrhea. The pack’s assessment is that the high TxGNN score most likely reflects graph proximity within a “female reproductive system” cluster rather than a real pharmacological signal.

A second, lower-ranked prediction in this pack (atypical coarctation of aorta, score 99.30%, evidence level L5) is even weaker: no clinical trials, no literature, and no known mechanistic pathway connecting a uterotonic/gastric-protective prostaglandin to a structural aortic anomaly. It is noted here for completeness but is not pursued further in this report.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27678099	2017	RCT	Reproductive Sciences	Low-dose mifepristone + self-administered misoprostol for ultra-early medical abortion (amenorrhea ≤35 days used only as a pregnancy-dating criterion, not as the treated condition)
25394644	2015	RCT	Reproductive Sciences	Dose-ranging RCT of lower-dose mifepristone + misoprostol (200 µg) for termination of ultra-early pregnancy
26405260	2015	Cohort	Human Reproduction	Low-dose mifepristone + misoprostol before expected menstruation for unintended pregnancy prevention
29974571	2018	Cohort	J Obstet Gynaecol Res	Safety/efficacy of self-administered low-dose mifepristone + misoprostol for early medical abortion
1486304	1992	Review	BMJ	Medical management of missed abortion and anembryonic pregnancy
26001691	2015	Review	J Obstet Gynaecol Can	Endometrial ablation for abnormal uterine bleeding (does not evaluate misoprostol or amenorrhea treatment)
37113350	2023	Case Report	Cureus	Acute fatty liver of pregnancy case report; amenorrhea appears only as a presenting symptom, not as a treated indication

None of these publications evaluate misoprostol as a therapeutic agent for amenorrhea; the association is indirect (shared reproductive-medicine context).

South Africa Market Information

Misoprostol has 0 SAHPRA registrations on file in this evidence pack and is classified as Not Marketed in South Africa. No product registrations, dosage forms, or approved indication text are available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale:

The predicted amenorrhea indication has no clinical trials and no literature that actually studies misoprostol as a treatment for amenorrhea — the associated publications are about pregnancy termination and heavy uterine bleeding, mechanistically distinct from (and largely opposite to) restoring menstrual function. The pack’s own rationale assesses this as a likely knowledge-graph artifact rather than a genuine signal.
Misoprostol is not currently registered or marketed in South Africa (0 SAHPRA registrations), so there is no existing regulatory foothold to build a repurposing pathway on.
The secondary prediction (atypical coarctation of aorta) is even weaker (L5, no trials, no literature, no plausible mechanism) and does not warrant further evaluation.

To proceed, the following is needed:

SAHPRA/TFDA-equivalent Professional Information (warnings, contraindications) — currently a Blocking data gap
Confirmed mechanism of action data from DrugBank — currently a High-severity data gap
Clarification of what “amenorrhea” denotes in this context (e.g., confirming non-pregnant status vs. therapeutic induction of menses) before any further evidence search is worthwhile
Original/reference indication data (South Africa or another jurisdiction) to properly assess mechanistic overlap with the predicted indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.